Avenue Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Alix MacLean

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage	33.0%
CEO tenure	2.2yrs
CEO ownership	n/a
Management average tenure	2.4yrs
Board average tenure	5.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Alix MacLean's remuneration changed compared to Avenue Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$15m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$1m	US$400k	-US$10m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$516k	US$154k	-US$4m

Compensation vs Market: Alix's total compensation ($USD1.21M) is above average for companies of similar size in the German market ($USD501.82K).

Compensation vs Earnings: Alix's compensation has increased whilst the company is unprofitable.

CEO

Alix MacLean (57 yo)

2.2yrs

Tenure

US$1,213,200

Compensation

Dr. Alexandra MacLean, also known as Alix, MD, serves as Director of Kent Imaging Inc. since January 2021. She is Chief Executive Officer at Avenue Therapeutics, Inc. since August 01, 2022 and serves as it...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Alexandra MacLean	CEO & Director	2.2yrs	US$1.21m	no data
David Jin	Interim CFO	2.6yrs	US$260.00k	0% $ 0
Lindsay Rosenwald	Executive Director	1.6yrs	US$104.00k	0.33% $ 9.9k
Scott Reines	Interim Chief Medical Officer	8.8yrs	US$123.12k	no data

2.4yrs

Average Tenure

63yo

Average Age

Experienced Management: 49Y's management team is considered experienced (2.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Alexandra MacLean	CEO & Director	1.6yrs	US$1.21m	no data
Lindsay Rosenwald	Executive Director	9.7yrs	US$104.00k	0.33% $ 9.9k
Jay Kranzler	Chairman of the Board	7.7yrs	US$212.19k	0.043% $ 1.3k
Neil Herskowitz	Non-Executive Independent Director	9.2yrs	US$164.00k	0.0084% $ 253.5
Faith Charles	Independent Director	2.4yrs	US$154.00k	0% $ 0
Curtis Oltmans	Independent Director	3.5yrs	US$154.00k	0.0031% $ 92.9

5.6yrs

Average Tenure

65yo

Average Age

Experienced Board: 49Y's board of directors are considered experienced (5.6 years average tenure).

Avenue Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Avenue Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Executive Director recently bought €234k worth of stock

Avenue Therapeutics, Inc., Annual General Meeting, Dec 28, 2022

Avenue Therapeutics, Inc. Announces Board Resignations

Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer

Less than half of directors are independent

Recent updates

New major risk - Financial position

Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

New major risk - Revenue and earnings growth

Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy

Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

New major risk - Revenue and earnings growth

the Staff of Nasdaq Determines to Delist Avenue Therapeutics’ Securities from Nasdaq Based Upon its Continued Non-Compliance with the Rule

New major risk - Financial position

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

Avenue Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Executive Director recently bought €234k worth of stock

Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc. Reaches Agreement with U.S. Food and Drug Administration on Key Elements of Phase 3 Safety Study for Intravenous Tramadol

Avenue Therapeutics Receives Non-Compliance Notice From The Nasdaq Stock Market LLC

Avenue Therapeutics, Inc. announced that it has received $0.24 million in funding

Avenue Therapeutics, Inc., Annual General Meeting, Dec 28, 2022

Avenue Therapeutics, Inc. (NasdaqCM:ATXI) acquired Baergic Bio, Inc.

Avenue Therapeutics, Inc. Announces Board Resignations

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $27.6 million.

Avenue Therapeutics, Inc. Submits Type A Meeting Request and Related Briefing Documents to the FDA

Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer

Less than half of directors are independent

Avenue Therapeutics, Inc. Announces Management Changes

Avenue Therapeutics Receives Non-Compliance Letter from Nasdaq

Avenue Therapeutics, Inc. Announces CEO Changes

Less than half of directors are independent

Avenue Therapeutics, Inc. Receives an Acknowledgement Letter from the Office of New Drugs of the Food and Drug Administration Regarding Avenue’s August 31, 2021 Formal Dispute Resolution Request

Avenue Therapeutics, Inc.(NasdaqCM:ATXI) dropped from Russell 3000E Index

Forecast breakeven pushed back to 2024

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Forecast breakeven pushed back to 2024

Avenue Therapeutics, Inc. Resubmits New Drug Application to the U.S. Food and Drug Administration for IV Tramadol

New 90-day high: €5.65

Avenue Therapeutics, Inc. Provides Regulatory Update for IV Tramadol

Avenue Therapeutics, Inc. Announces Thomas G. Moore to Resign from the Board of Directors of the Company, Effective December 31, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age